

**PH2 - 2. CD-1 Rezoning: 150 West 4th Avenue - Support**

Date Received	Time Created	Subject	Position	Content	Name	Organization	Contact Info	Neighbourhood	Attachment
11/15/2021	14:23	PH2 - 2. CD-1 Rezoning: 150 West 4th Avenue	Support	Dear Mayor and Council, My name is Dan Jordan and I'm a commercial broker who specializes in the Mount Pleasant Area. I'm writing to express my fervent support for the Dayhu development at 150 W 4th Avenue. In my experience, it's high time we densify this area. We have reached a critical point in time, where if we say no, nothing will ever change. I can say with confidence that the demand for industrial space in Vancouver is only increasing, and we need to accommodate for that or else lose some of our industry. This proposal is beautiful and will fit in nicely to the area if approved. It has enhanced the public realm and will create a safe and walkable environment for everyone, not just those that work close by. Let's keep the momentum going and capitalize on this big opportunity. It not only benefits the applicant, but the neighbourhood, and honesty our city as a whole. AbCellera is an amazing company that does good and is always seeking to do better. I'd be proud to have them remain in this community. Thank you, Dan Jordan	Dan Jordan		s.22(1) Personal and Confiden	Unknown	No web attachments.
11/16/2021	14:18	PH2 - 2. CD-1 Rezoning: 150 West 4th Avenue	Support	See Letter	Robert Calder		s.22(1) Personal and Co	Fairview	Appendix A
11/16/2021	15:31	PH2 - 2. CD-1 Rezoning: 150 West 4th Avenue	Support	Dear City Council and Planning Staff First, please forgive my written submission in lieu of attending the public hearing tonight. However, despite personal matters arising, I felt strongly compelled to speak in favour of moving forward with the rezoning application as submitted by Abcellera for their new biotech campus to be located at 150 West 4th Avenue. Throughout my career, I have remained tied to the health and well-being of British Columbians, first as a paramedic with the BC Ambulance Service, then as a researcher at the BC Cancer Research Center located just down the road on 10th Avenue here in Vancouver, and now as a member of the executive team of another Vancouver-based biotechnology company, Zymeworks. In each of these roles, I've sought to positively impact the lives of more and more patients, and it was the understanding that the application of cutting-edge biomedical R&D, such as those undertaken by Abcellera, can impact the lives of millions of patients around the globe. Having had the unique opportunity to join a start-up biotechnology company here in Vancouver in 2007, and moreover to help build it from a handful of passionate start-up researchers to a company of over 500 employees across north America, I feel well positioned to share some perspective on the impact of the proposed Abcellera campus. Since the mid 2000's when QLT and Angiotech scaled back operations in the city, Vancouver has struggled to attract and retain key talent in the biopharmaceutical sector. While companies like Zymeworks have made significant inroads, the persistent struggle to lure top global talent away from cities like Boston, San Francisco and San Diego has been constant. I strongly believe that a key feature missing in our local ecosystem is a geographically centred cluster of leading-edge biotech companies 'an area where peers and colleagues can interact to build dynamic momentum, which in turn can create and lure new biotech spinouts, start-ups, and existing companies. Along with Zymeworks, which will be moving into new offices 114 East 4th Avenue in February, the Abcellera campus has the potential to transform Mount Pleasant into a global life sciences hub, creating just such a cluster. It can be a lynchpin in creating a dynamic cluster that cements Vancouver's commitment to the knowledge-based economy and acts as a key driver in improving the health of people around the globe. The decision made by Council and planning staff in this matter has the power to reach beyond the walls of this chamber. It will reverberate in the development of novel therapies and future treatments in areas such as infectious diseases, diseases, diabetes, epilepsy, cancer and other life-altering diseases. As we say at Zymeworks, our missions is enabling patients to return home to their loved ones, disease free. Today I hope Counsel and Planning Staff join me in voicing their support for the Abcellera campus and thereby join us in supporting this mission.	Neil Klompas		s.22(1) Personal and Confidential	Unknown	Appendix B



Dear Mayor and Council,

My name is Rob Calder and I'm writing in support of the DAYHU development at 150 W 4<sup>th</sup> Avenue. I have lived and worked in the neighbourhood for over 10 years and I support the proposal for additional density in the neighbourhood.

We operate two companies (Audio Post Production, Event Management) as well as manage a shared office space that houses two digital content companies, a video production company and a marketing company. We have seen positive growth in the neighbourhood that has contributed to both the culture and safety of our businesses and offices.

The Mount Pleasant Industrial Area has also long been home to many different and diverse organizations over the years. Approving a project of this calibre will continue to help keep Vancouver at the forefront of innovation and economic growth while enriching street level small businesses and activities.

I strongly believe that you should vote in favour of this project and help create a more vibrant and sustainable neighbourhood for all to enjoy.

Thank you,

A handwritten signature in black ink, appearing to read 'Rob Calder', followed by a period.

Robert Calder  
Owner & Partner  
Secret Study Projects, Vaudeville Sound



November 16, 2021

City of Vancouver  
City Council and Planning Staff  
453 West 12th Avenue  
Vancouver BC, V5Y 1V4

**Re: 150 West 4<sup>th</sup> Avenue - Public Hearing on Rezoning**

Dear City Council and Planning Staff

First, please forgive my written submission in lieu of attending the public hearing tonight. However, despite personal matters arising, I felt strongly compelled to speak in favour of moving forward with the rezoning application as submitted by Abcellera for their new biotech campus to be located at 150 West 4<sup>th</sup> Avenue.

Throughout my career, I have remained inexorably tied to the health and well-being of British Columbians, first as a paramedic with the British Columbia Ambulance Service in the lower mainland and capital regional district, then as a researcher at the BC Cancer Research Center located just down the road on 10<sup>th</sup> Avenue here in Vancouver, and now as a member of the executive team of another Vancouver-based biotechnology company, Zymeworks.

In each of these roles, I've sought to positively impact the lives of more and more patients, and it was the understanding that the application of cutting-edge biomedical research, such as the research and development undertaken by Abcellera, can impact the lives of millions of patients around the globe.

Having had the unique opportunity to join a start-up biotechnology company here in Vancouver in 2007, and moreover to help build it from a handful of passionate start-up researchers to a company of over 500 employees across north America, I feel well positioned to share some perspective on the impact of the proposed Abcellera campus.

Since the mid 2000's when QLT Therapeutics and Angiotech Pharmaceuticals significantly scaled back operations in the city, Vancouver has struggled to attract and retain key talent in the biopharmaceutical sector. While companies like Zymeworks have made significant inroads, the persistent struggle to lure top global talent away from cities like Boston, San Francisco and San Diego has been constant.

I strongly believe that a key feature missing in our local ecosystem is a geographically centred cluster of prominent, leading-edge biotech companies – an area where peers and colleagues can interact both professional and privately to build dynamic momentum, which in turn can create and lure new biotech spinouts, start-ups, and existing biopharma companies. This model underpins the success of Boston in luring new biotechnology companies to Massachusetts.

Along with Zymeworks, which will be moving into new offices 114 East 4<sup>th</sup> Avenue in February, the Abcellera campus has the potential to transform Mount Pleasant into a globally recognized life sciences hub, creating just such a cluster. I believe it will be a lynchpin in creating a dynamic cluster that cements Vancouver's commitment to the knowledge-based economy and acts as a key driver in improving the health of people around the globe.



The decision made by Council and planning staff in this matter has the power to reach beyond the walls of this chamber. It will reverberate in the development of novel therapies and future treatments in areas such as infectious diseases, diabetes, epilepsy, cancer and other life-altering diseases. The potential to be a part of such advances is what drew me to build a career in biotech, and it still motivates me to this day. As we say at Zymeworks, our mission is enabling patients to return home to their loved ones, disease free. Today I hope Counsel and Planning Staff join me in voicing their support for the rezoning initiative for the Abcellera campus and thereby join all of us in supporting this mission.

Yours very truly,

A handwritten signature in blue ink, appearing to read "Neil Klompas", followed by a horizontal line and a small loop at the end.

Neil Klompas, CPA, CA  
*Chief Financial Officer &  
Executive VP, Business Operations  
Zymeworks Inc.*